Department of Pathology, University Medical Center Freiburg, Freiburg, Germany.
Faculty of Biology, University of Freiburg, Freiburg, Germany.
Bone Marrow Transplant. 2017 Aug;52(8):1144-1155. doi: 10.1038/bmt.2017.81. Epub 2017 May 8.
Natural killer (NK) cell subpopulations from 8 HLA-matched but killer cell immunoglobulin-like receptor (KIR)/HLA-ligand-mismatched patient-donor pairs were analyzed in the course of allogeneic hematopoietic stem cell transplantation (HCT). The patients' post-transplantation NKG2A/LIR-1 NK cells, which expressed only inhibitory KIRs for which the patient had no HLA class I ligands, showed higher cytotoxic capacity than the NKG2A/LIR-1 NK cells lacking any inhibitory KIRs that remained tolerant throughout the course of HCT. The NKG2A NK cell subpopulations displayed the highest levels of cytotoxic activation, which appeared to be significantly enhanced in comparison with that in allogeneic graft's donors. LIR-1 NK cells were much more frequent after HCT than LIR-1 NK cells and LIR-1 expression on NKG2A or NKG2A NK cells was associated with significantly lower cytotoxic activities. Thus NKG2A/LIR-1 NK cells expressing only HLA-mismatched KIRs show a partial break in tolerance in the first year following HCT. The failure to exclude LIR-1 cells within the NKG2A NK cell subset in previous studies could explain the earlier conflicting results. Thus systemic immune activation in patients following HCT augments the GvL effect through both increasing overall NK cell activities and partially breaking tolerance of unlicensed NK cells.
在异基因造血干细胞移植 (HCT) 过程中,分析了 8 对 HLA 匹配但杀伤细胞免疫球蛋白样受体 (KIR)/HLA 配体匹配的患者-供体的自然杀伤 (NK) 细胞亚群。移植后表达仅对患者无 HLA Ⅰ类配体的抑制性 KIR 的 NKG2A/LIR-1 NK 细胞具有更高的细胞毒性,而在 HCT 过程中保持耐受的缺乏任何抑制性 KIR 的 NKG2A/LIR-1 NK 细胞的细胞毒性较低。NKG2A NK 细胞亚群显示出最高水平的细胞毒性激活,与同种异体移植物供体相比,这种激活似乎明显增强。HCT 后 LIR-1 NK 细胞比 LIR-1 NK 细胞更常见,NKG2A 或 NKG2A NK 细胞上的 LIR-1 表达与显著降低的细胞毒性活性相关。因此,在 HCT 后第一年,仅表达 HLA 不匹配 KIR 的 NKG2A/LIR-1 NK 细胞表现出部分耐受破坏。以前的研究中未能在 NKG2A NK 细胞亚群中排除 LIR-1 细胞可能解释了之前相互矛盾的结果。因此,HCT 后患者的全身免疫激活通过增加 NK 细胞的整体活性和部分破坏未授权 NK 细胞的耐受性来增强移植物抗白血病效应。